Taha Bartu HAYAL, Aysegul DOGAN, Hatice Burcu SİSLİ, Binnur KİRATLİ, Fikrettin SAHİN

Ubiquitin-specific protease 7 downregulation suppresses breast cancer in vitro

Because breast cancer is complicated at the pathological, histological, clinical, and molecular levels, identification of new genetic targets against carcinogenic pathways is required to generate clinically relevant treatment options. In the current study, ubiquitin-specific protease 7 (USP7), which regulates various cellular pathways including Mdm2, p53, and NF-kappa B, was selected as a potential gene editing strategy for breast cancer in vitro. Anticancer activity of USP7 gene suppression has been evaluated through cell proliferation, gene expression, cell cycle, sphere dissemination, and cell migration analysis. Here, siRNA and shRNA strategies and an allosteric small-molecule inhibitor of USP7 were used to define potential anticancer activity against MCF7 and T47D human breast cancer cell lines. Both blockage of deubiquitination by p5091 and knockdown of USP7 reduced cell proliferation, cell migration, colony formation, and sphere dissemination for both MCF7 and T47D breast cancer cell lines. Restriction of USP7 activity strongly enhanced apoptotic gene expression and reduced metastatic ability of breast cancer cell lines. This study describes one potential molecular target for the suppression of breast cancer proliferation and metastasis. Identification of USP7 as a promising gene editing candidate might open up the possibility of new molecular drug research in targeting the ubiquitination pathway in cancer.

Keywords:

Ubiquitination, breast cancer, USP7, p5091, gene editing,

PDF

___

Al-Mahmood S, 2018, DRUG DELIV TRANSL RE, V8, P1483, DOI 10.1007/s13346-018-0551-3
Amerik AY, 2004, BBA-MOL CELL RES, V1695, P189, DOI 10.1016/j.bbamcr.2004.10.003
Borner C, 2014, CELL DEATH DIFFER, V21, P187, DOI 10.1038/cdd.2013.169
Brahemi G, 2010, J MED CHEM, V53, P2757, DOI 10.1021/jm901757t
Carra G, 2017, ONCOTARGET, V8, P35508, DOI 10.18632/oncotarget.16348
Chen JD, 2016, CSH PERSPECT MED, V6, DOI 10.1101/cshperspect.a026104
Ciechanover A, 2013, BIOORGAN MED CHEM, V21, P3400, DOI 10.1016/j.bmc.2013.01.056
Demirci S, 2019, CHEM BIOL DRUG DES, V94, P1584, DOI 10.1111/cbdd.13575
Dey A, 2007, CELL CYCLE, V6, P2178, DOI 10.4161/cc.6.17.4643
DiGirolamo CM, 1999, BRIT J HAEMATOL, V107, P275, DOI 10.1046/j.1365-2141.1999.01715.x
Dogan A, 2014, BIOL TRACE ELEM RES, V162, P72, DOI 10.1007/s12011-014-0104-7
Gallo LH, 2017, CELL CYCLE, V16, P634, DOI 10.1080/15384101.2017.1288326
Gasco M, 2002, BREAST CANCER RES, V4, P70, DOI 10.1186/bcr426
Gupta A, 2019, BIOMED PHARMACOTHER, V109, P484, DOI 10.1016/j.biopha.2018.10.155
Hoeller D, 2009, NATURE, V458, P438, DOI 10.1038/nature07960
Hosseini H, 2016, NATURE, V540, P552, DOI 10.1038/nature20785
Hu T, 2019, MOL CARCINOGEN, V58, P42, DOI 10.1002/mc.22905
Huang KT, 2004, BIOTECHNIQUES, V37, P406, DOI 10.2144/04373ST05
Kessler BM, 2007, J PROTEOME RES, V6, P4163, DOI 10.1021/pr0702161
King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652
Kuo CT, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-04718-1
Lai H, 2004, BREAST CANCER RES TR, V83, P57, DOI 10.1023/B:BREA.0000010699.53742.60
Li SY, 2017, AM J CANCER RES, V7, P448 .
Lim LY, 2009, BRIT J CANCER, V101, P1606, DOI 10.1038/sj.bjc.6605335
Liu M, 2016, CELL MOL GASTROENTER, V2, P63, DOI 10.1016/j.jcmgh.2015.08.008
Lyden D, 2011, CANC METASTASIS BIOL .
Mali Shrikant, 2013, Indian J Hum Genet, V19, P3, DOI 10.4103/0971-6866.112870
Morra F, 2017, ONCOTARGET, V8, P31815, DOI 10.18632/oncotarget.16463
Mourtzoukou D, 2018, UBIQUITINATION GOVER, P179
Nakanishi A, 2014, INT J ONCOL, V44, P1813, DOI 10.3892/ijo.2014.2377
Navarro E, 2015, CLIN CHIM ACTA, V439, P231, DOI 10.1016/j.cca.2014.10.017
Nijman SMB, 2005, CELL, V123, P773, DOI 10.1016/j.cell.2005.11.007
Ohta T, 2004, ONCOGENE, V23, P2079, DOI 10.1038/sj.onc.1207371
Oren M, 2003, CELL DEATH DIFFER, V10, P431, DOI 10.1038/sj.cdd.4401183
Pal A, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0461-3
Parrales A, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00288
Siegel RL, 2020, CA-CANCER J CLIN, V70, P7, DOI 10.3322/caac.21590
Simpson PT, 2005, J PATHOL, V205, P248, DOI 10.1002/path.1691
Song MS, 2008, EMBO J, V27, P1863, DOI 10.1038/emboj.2008.115
Sowa ME, 2009, CELL, V138, P389, DOI 10.1016/j.cell.2009.04.042
Tavana O, 2018, CELL CYCLE, V17, P823, DOI 10.1080/15384101.2018.1456293
Wang MY, 2017, CELL PHYSIOL BIOCHEM, V43, P1755, DOI 10.1159/000484062
Wang Q, 2016, J CLIN INVEST, V126, P2205, DOI 10.1172/JCI85747
Wang ZR, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00427
WEISWALD LB, 2014, NEO, V17, P1, DOI DOI 10.1016/J.NEO.2014.12.004
Wirapati P, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2124
Xia XH, 2019, CANCER LETT, V465, P118, DOI 10.1016/j.canlet.2019.09.003
Yoshimura T, 2016, ONCOTARGET, V7, P49065, DOI 10.18632/oncotarget.7529
Yu S, 2017, BIOCHEM BIOPH RES CO, V486, P752, DOI 10.1016/j.bbrc.2017.03.114